Patents by Inventor Martine Jandrot-Perrus
Martine Jandrot-Perrus has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230391869Abstract: The present invention relates to an isolated humanized protein binding to human Glycoprotein VI (hGPVI) for treating a GPVI-related condition in a subject in need thereof, wherein said isolated humanized protein is to be administered during at least 2 hours to the subject, preferably during at least 4 to 6 hours.Type: ApplicationFiled: May 12, 2023Publication date: December 7, 2023Inventors: Philippe BILLIALD, Martine JANDROT-PERRUS, Gilles AVENARD
-
Patent number: 11692033Abstract: The present invention relates to an isolated humanized protein binding to human Glycoprotein VI (hGPVI) for treating a GPVI-related condition in a subject in need thereof, wherein said isolated humanized protein is to be administered during at least 2 hours to the subject, preferably during at least 4 to 6 hours.Type: GrantFiled: February 2, 2018Date of Patent: July 4, 2023Assignees: Acticor Biotech, Université Paris Cité, Université Paris-XIII, Inserm (Institut National de la Santé et de la Recherche Médicale), Université Paris-SaclayInventors: Philippe Billiald, Martine Jandrot-Perrus, Gilles Avenard
-
Publication number: 20200384106Abstract: The present invention relates to humanized anti-human GPVI antibodies and uses thereof.Type: ApplicationFiled: August 20, 2020Publication date: December 10, 2020Inventors: Philippe BILLIALD, Martine JANDROT-PERRUS
-
Patent number: 10842870Abstract: The present invention relates to humanized anti-human GPVI antibodies and uses thereof.Type: GrantFiled: August 5, 2016Date of Patent: November 24, 2020Assignees: ACTICOR BIOTECH, UNIVERSITE DE PARIS, UNIVERSITÉ PARIS-XIII, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), UNIVERSITE PARIS-SACLAYInventors: Philippe Billiald, Martine Jandrot-Perrus
-
Publication number: 20200087403Abstract: Thrombosis is the main cause of morbidity and mortality in patients with JAK2V617F positive myeloproliferative neo-plasms (MPN). Recent works reported the presence of JAK2V617F in endothelial cells in some MPN patients. Here, the inventors show that JAK2V617F endothelial cells promote thrombosis through induction of endothelial P-selectin expression and thus demonstrate that P-selectin blockade was sufficient to reduce the increased propensity of thrombosis. Accordingly the present invention relates to a method of treating thrombosis in a patient suffering from a myeloproliferative neoplasm comprising administering to the patient a therapeutically effective amount of a P-selectin antagonist.Type: ApplicationFiled: March 14, 2018Publication date: March 19, 2020Inventors: Chloé JAMES, Thierry COUFFINHAL, Virginie GOURDOU-LATYSZENOK, Alexandre GUY, Martine JANDROT-PERRUS
-
Publication number: 20190367608Abstract: The present invention relates to an isolated humanized protein binding to human Glycoprotein VI (hGPVI) for treating a GPVI-related condition in a subject in need thereof, wherein said isolated humanized protein is to be administered during at least 2 hours to the subject, preferably during at least 4 to 6 hours.Type: ApplicationFiled: February 2, 2018Publication date: December 5, 2019Applicants: Acticor Biotech, Université Paris Diderot - Paris 7, Université Paris-XIII, Nserm (Institut National de la Santé et de la Recherche Médicale), Université Paris-Sud 11Inventors: Philippe BILLIALD, Martine JANDROT-PERRUS, Gilles AVENARD
-
Publication number: 20180236071Abstract: The present invention relates to humanized anti-human GPVI antibodies and uses thereof.Type: ApplicationFiled: August 5, 2016Publication date: August 23, 2018Inventors: Philippe BILLIALD, Martine JANDROT-PERRUS
-
Patent number: 9999679Abstract: The invention relates to a vector targeting thrombus, having t-PA binding property consisting of a thrombus targeting fucoidan moiety, which is covalently linked to one or more t-PA binding amino groups by the reducing end of the said fucoidan moiety.Type: GrantFiled: March 21, 2014Date of Patent: June 19, 2018Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE PARIS XIII PARIS NORD, UNIVERSITE PARIS DIDEROT—PARIS 7Inventors: Stephane Loyau, Martine Jandrot-Perrus, Didier Letourneur, Frederic Chaubet, Benoit Ho-Tin-Noe, Murielle Maire, Jean-Baptiste Michel
-
Publication number: 20160279249Abstract: The invention relates to a vector targeting thrombus, having t-PA binding property consisting of a thrombus targeting fucoidan moiety, which is covalently linked to one or more t-PA binding amino groups by the reducing end of the said fucoidan moiety.Type: ApplicationFiled: March 21, 2014Publication date: September 29, 2016Applicants: INSTITUT DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE PARIS XIII PARIS NORD, UNIVERSITE PARIS DIDEROT - PARIS 7Inventors: Stephane LOYAU, Martine JANDROT-PERRUS, Didier LETOURNEUR, Frederic CHAUBET, Benoit HO-TIN-NOE, Murielle MAIRE, Jean-Baptiste MICHEL
-
Patent number: 9045538Abstract: The present invention relates to a single chain variable fragment (scFv 9O12.2) directed against human glycoprotein VI, constituted of the VH and VL domains of 9 O12.2.2 monoclonal antibody linked via a (Gly4Ser)3 peptide and followed by a “c-myc” flag, represented by SEQ ID NO:1. The invention also concerns functional variants of said scFv 9O12.2 fragment with identical heavy and light chains complementary determining regions 1, 2 and 3, and preferably humanized functional variants such as the humanized scFv fragments represented by SEQ ID NO:28 or SEQ ID NO:47. The invention also relates to nucleic acids encoding such a scFv fragment, expression vectors and host cells to produce such a scFv fragment, as well as therapeutic uses of such a scFv fragment.Type: GrantFiled: October 26, 2007Date of Patent: June 2, 2015Assignee: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)Inventors: Martine Jandrot-Perrus, Philippe Billiald, Julien Muzard
-
Patent number: 9045540Abstract: The present invention relates to a single chain variable fragment (scFv 9O12.2) directed against human glycoprotein VI, constituted of the VH and VL domains of 9 O12.2.2 monoclonal antibody linked via a (Gly4Ser)3 peptide and followed by a “c-myc” flag, represented by SEQ ID NO:1. The invention also concerns functional variants of said scFv 9O12.2 fragment with identical heavy and light chains complementary determining regions 1, 2 and 3, and preferably humanized functional variants such as the humanized scFv fragments represented by SEQ ID NO:28 or SEQ ID NO:47. The invention also relates to nucleic acids encoding such a scFv fragment, expression vectors and host cells to produce such a scFv fragment, as well as therapeutic uses of such a scFv fragment.Type: GrantFiled: December 21, 2012Date of Patent: June 2, 2015Assignee: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)Inventors: Martine Jandrot-Perrus, Philippe Billiald, Julien Muzard
-
Patent number: 9029095Abstract: The invention relates to methods and kits for determining platelet susceptibility to activation in a patient. More particularly, the present invention relates to a method for determining platelet susceptibility to activation in a patient, comprising a step consisting of measuring the level of GPVI dimers at the platelet surface in a blood sample obtained from said patient.Type: GrantFiled: December 1, 2011Date of Patent: May 12, 2015Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Paris DiderotInventors: Martine Jandrot-Perrus, Laurent Feldman, Stéphane Loyau
-
Publication number: 20130310401Abstract: The invention relates to methods and kits for determining platelet susceptibility to activation in a patient. More particularly, the present invention relates to a method for determining platelet susceptibility to activation in a patient, comprising a step consisting of measuring the level of GPVI dimers at the platelet surface in a blood sample obtained from said patient.Type: ApplicationFiled: December 1, 2011Publication date: November 21, 2013Applicants: UNIVERSITE PARIS DIDEROT, Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Martine Jandrot-Perrus, Laurent Feldman, Stéphane Loyau
-
Publication number: 20130189259Abstract: The present invention relates to a single chain variable fragment (scFv 9O12.2) directed against human glycoprotein VI, constituted of the VH and VL domains of 9 O12.2.2 monoclonal antibody linked via a (Gly4Ser)3 peptide and followed by a “c-myc” flag, represented by SEQ ID NO:1. The invention also concerns functional variants of said scFv 9O12.2 fragment with identical heavy and light chains complementary determining regions 1, 2 and 3, and preferably humanized functional variants such as the humanized scFv fragments represented by SEQ ID NO:28 or SEQ ID NO:47. The invention also relates to nucleic acids encoding such a scFv fragment, expression vectors and host cells to produce such a scFv fragment, as well as therapeutic uses of such a scFv fragment.Type: ApplicationFiled: December 21, 2012Publication date: July 25, 2013Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale)Inventors: Martine Jandrot-Perrus, Philippe Billiald, Julien Muzard
-
Patent number: 8466258Abstract: The present invention relates to diagnostic imaging and in particular to the diagnostic imaging of fibrosis. More particularly, the present invention provides a polypeptides, cyclic polypeptides and pharmaceutical compositions suitable for the non-invasive visualization of fibrosis. The polypeptide of the invention may comprise an amino acid sequence consisting of: X1-X2-M-H-G-L-X7-L-X9-X10-D-E (SEQ ID NO: 1) wherein amino acid X1 is R, F or P; amino acid X2 is F or V; amino acid X7 is Q, H or L; amino acid X9 is W or G and amino acid X10 is A or D.Type: GrantFiled: December 11, 2008Date of Patent: June 18, 2013Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Universite Paris Diderot—Paris 7Inventors: Martine Jandrot-Perrus, Julien Muzard, Philippe Billiald, Dominique le Guludec, Laure Sarda, Alain Meulemans
-
Publication number: 20110182899Abstract: The present invention relates to a single chain variable fragment (scFv 9O12.2) directed against human glycoprotein VI, constituted of the VH and VL domains of 9 O12.2.2 monoclonal antibody linked via a (Gly4Ser)3 peptide and followed by a “c-myc” flag, represented by SEQ ID NO:1. The invention also concerns functional variants of said scFv 9O12.2 fragment with identical heavy and light chains complementary determining regions 1, 2 and 3, and preferably humanized functional variants such as the humanized scFv fragments represented by SEQ ID NO:28 or SEQ ID NO:47. The invention also relates to nucleic acids encoding such a scFv fragment, expression vectors and host cells to produce such a scFv fragment, as well as therapeutic uses of such a scFv fragment.Type: ApplicationFiled: October 26, 2007Publication date: July 28, 2011Inventors: Martine Jandrot-Perrus, Philippe Billiald, Julien Muzard
-
Publication number: 20100303724Abstract: The present invention relates to diagnostic imaging and in particular to the diagnostic imaging of fibrosis. More particularly, the present invention provides a polypeptides, cyclic polypeptides and pharmaceutical compositions suitable for the non-invasive visualization of fibrosis. The polypeptide of the invention may comprise an amino acid sequence consisting of: X1-X2-M-H-G-L-X7-L-X9-X10-D-E wherein amino acid X1 is R, F or P; amino acid X2 is F or V; amino acid X7 is Q, H or L; amino acid X9 is W or G and amino acid X10 is A or D.Type: ApplicationFiled: December 11, 2008Publication date: December 2, 2010Applicant: UNIVERSITE PARIS DIDEROT - PARIS 7Inventors: Martine Jandrot-Perrus, Julien Muzard, Philippe Billiald, Dominique le Guludec, Laure Sarda, Alain Meulemans
-
Publication number: 20100261200Abstract: The invention provides isolated nucleic acid molecules and polypeptide molecules that encode glycoprotein VI, a platelet membrane glycoprotein that is involved platelet-collagen interactions. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: January 20, 2010Publication date: October 14, 2010Inventors: Samantha J. Busfield, Jean-Luc Villeval, Martine Jandrot-Perrus, William Vainchencker
-
Publication number: 20060216291Abstract: The invention provides isolated nucleic acid molecules and polypeptide molecules that encode glycoprotein VI, a platelet membrane glycoprotein that is involved platelet-collagen interactions. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: June 6, 2006Publication date: September 28, 2006Inventors: Samantha Busfield, Jean-Luc Villeval, Martine Jandrot-Perrus, William Vainchencker
-
Patent number: 6989144Abstract: The invention provides isolated nucleic acid molecules and polypeptide molecules that encode glycoprotein V1, a platelet membrane glycoprotein that is involved platelet-collagen interactions. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the exposure vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: June 30, 2000Date of Patent: January 24, 2006Assignee: Millennium Pharmaceuticals, Inc.Inventors: Samatha J. Busfield, Jean-Luc Villeval, Martine Jandrot-Perrus, William Vainchencker, Davinder Singh Gill, Ming Diana Qian, Gillian Kingsbury